Received: 19 May 2019
Accepted: 17 February 2020
First Online: 24 February 2020
Ethics approval and consent to participate
: The study was approved by the ethical committee of the Faculty of Medicine of the University in Cologne, Germany, on 02 March 2012 (reference number 11–334) and was conducted according to the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization (now: International Council for Harmonization). All patients gave signed, informed consent to participate in the study.
: Not applicable.
: CBW reports personal fees from Roche, Celgene, RedHill and Ipsen; grants from Roche, outside the submitted work. TK has nothing to disclose. BG reports research funding from Sirtex; speaker’s honoraria from Sirtex, Roche, Amgen, Pfizer, Celgene, Merck and Novartis; advisory board memberships at Sirtex, Roche and Amgen; travel grants from Merck, Amgen, Celgene and B. Braun Travacare. LH has nothing to disclose. MF has nothing to disclose. PM has nothing to disclose. MR has nothing to disclose. FK reports personal fees from Sirtex and Shire, outside the submitted work. VH reports grants, personal fees and non-financial support from Merck KGaA, Roche, Amgen, Sirtex and Bayer; grants and personal fees from Celgene and Boehringer Ingelheim; personal fees and non-financial support from Sanofi; personal fees from Lilly, Baxalta, Taiho, Merrimack and Servier; grants from Shire and Pfizer, outside the submitted work. AB reports employment at Roche. DTW reports consulting fees from Bayer Health Pharma, BMS, Celgene, Novartis, Roche Pharma AG, Shire Baxelta and Sirtex; presenter fees from Bayer Health Pharma, BMS, Celgene, Novartis, Shire Baxelta and Sirtex; research grants from Roche Pharma AG.